This mechanism provides a potential explanation why a limited subset of BRAFV600E melanoma cells are exquisitely sensitive to MEK inhibition and supports the rationale combination of AKT and MEK inhibition as a viable cancer therapeutic strategy. Here, MAP2K7 is linked to melanoma.